Apellis Pharmaceuticals, Inc.

Quick facts

Marketed products

• Soliris · Neuroscience

Phase 3 pipeline

• APL-2 · Immunology
  APL-2 is a complement C3 inhibitor that blocks the central component of the complement cascade to reduce inflammation and tissue damage.
• APL-2, Pegcetacoplan · Immunology / Rare Disease
  Pegcetacoplan is a complement C3 inhibitor that blocks the activation and amplification of the complement cascade by targeting C3.

Phase 2 pipeline

• APL2 · Immunology
  APL2 is a complement C3 inhibitor that blocks the central component of the complement cascade to reduce inflammation and tissue damage.

Phase 1 pipeline

• APL-9

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Apellis Pharmaceuticals, Inc. portfolio CI brief
• Apellis Pharmaceuticals, Inc. pipeline updates RSS